- Previous Close
9.30 - Open
9.36 - Bid 9.07 x 100
- Ask 9.53 x 100
- Day's Range
9.15 - 9.49 - 52 Week Range
3.72 - 19.30 - Volume
37,920 - Avg. Volume
155,045 - Market Cap (intraday)
305.04M - Beta (5Y Monthly) 1.69
- PE Ratio (TTM)
-- - EPS (TTM)
-3.31 - Earnings Date Nov 8, 2024 - Nov 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.60
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.
pepgen.comRecent News: PEPG
View More
Performance Overview: PEPG
Trailing total returns as of 10/7/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PEPG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PEPG
View MoreValuation Measures
Market Cap
303.41M
Enterprise Value
161.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.96
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-31.89%
Return on Equity (ttm)
-58.97%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-89.14M
Diluted EPS (ttm)
-3.31
Balance Sheet and Cash Flow
Total Cash (mrq)
161.31M
Total Debt/Equity (mrq)
12.52%
Levered Free Cash Flow (ttm)
-44.69M
Research Analysis: PEPG
View MoreCompany Insights: PEPG
PEPG does not have Company Insights